Research Articles
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Meaghan Wall
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Gretchen Poortinga
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Kym L. Stanley
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Ralph K. Lindemann
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Michael Bots
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Christopher J. Chan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Megan J. Bywater
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Kathryn M. Kinross
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Megan V. Astle
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Kelly Waldeck
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Katherine M. Hannan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Jake Shortt
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Mark J. Smyth
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Scott W. Lowe
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Ross D. Hannan
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Richard B. Pearson
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Ricky W. Johnstone
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
Grant A. McArthur
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
DOI: 10.1158/2159-8290.CD-12-0404 Published January 2013
Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 3, Issue 1, pp. 82-95
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 30, 2012
- Revision received October 22, 2012
- Accepted October 23, 2012
- Published first December 14, 2012.
Article Versions
- Previous version (December 14, 2012 - 06:45).
- Previous version (December 17, 2012 - 09:36).
- You are viewing the most recent version of this article.
Copyright & Usage
©2012 American Association for Cancer Research.
Author Information
- Meaghan Wall1,3,4,
- Gretchen Poortinga1,3,
- Kym L. Stanley1,
- Ralph K. Lindemann1,13,
- Michael Bots1,
- Christopher J. Chan1,9,
- Megan J. Bywater1,
- Kathryn M. Kinross1,
- Megan V. Astle1,
- Kelly Waldeck1,
- Katherine M. Hannan1,
- Jake Shortt1,3,
- Mark J. Smyth1,6,7,
- Scott W. Lowe11,12,
- Ross D. Hannan1,5,7,8,10,
- Richard B. Pearson1,5,7,8,
- Ricky W. Johnstone1,6,7 and
- Grant A. McArthur1,2,3,6,7
- Authors' Affiliations:1Divisions of Research and 2Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria; 3Department of Medicine and 4Victorian Cancer Cytogenetics Service, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 5Departments of Biochemistry and Molecular Biology and 6Pathology and 7Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; 8Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, and 9Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Prahran, Victoria; and 10School of Biomedical Sciences, The University of Queensland, Queensland, Australia; 11Cold Spring Harbor Laboratory, Cold Spring Harbor; 12Howard Hughes Medical Institute, Cold Spring Harbor, New York; and 13Merck Serono TA Oncology, Merck KGaA, Darmstadt, Germany
- Corresponding Author:
Grant McArthur, Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia. Phone: 61-3-9656-1954; Fax: 61-3-9656-3717; E-mail: grant.mcarthur{at}petermac.org
M. Wall and G. Pootinga contributed equally to this work.
January 2013
Volume 3, Issue 1
Volume 3, Issue 1
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Cancer Discov January 1 2013 (3) (1) 82-95; DOI: 10.1158/2159-8290.CD-12-0404
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall, Gretchen Poortinga, Kym L. Stanley, Ralph K. Lindemann, Michael Bots, Christopher J. Chan, Megan J. Bywater, Kathryn M. Kinross, Megan V. Astle, Kelly Waldeck, Katherine M. Hannan, Jake Shortt, Mark J. Smyth, Scott W. Lowe, Ross D. Hannan, Richard B. Pearson, Ricky W. Johnstone and Grant A. McArthur
Cancer Discov January 1 2013 (3) (1) 82-95; DOI: 10.1158/2159-8290.CD-12-0404
Jump to section
Advertisement